Artelo Biosciences Inc ARTL

As reported, ART27.13 produced approximately 40% weight loss in combination with semaglutide and approximately 20% as monotherapy, comparable to semaglutide, in obese mice over four weeks Application expands Artelo’s intellectual property position for ART27.13 into obesity, where J.P. Morgan has projected the global GLP-1 market could reach $200 billion by 2030 New findings show the combination further improved oral glucose tolerance and increased bone mineral density, an effect not observed in

Once-daily, oral ART27.13 reduced body weight by approximately 20% in obese mice, matching the weight loss achieved with semaglutide, the active ingredient in Ozempic® and Wegovy® Combining ART27.13 with semaglutide produced approximately 40% weight loss – double that of semaglutide alone Results indicate that ART27.13 may possess the profile of a “metabolic regulator” capable of differentially modifying body weight and other parameters depending on the metabolic phenotype being treated SOLANA B

SOLANA BEACH, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that Gregory D. Gorgas, CEO of Artelo Biosciences, will be participating in the H.C. Wainwright 28th Annual Global Investment Conference being held September 14-16, 2026

Shares Expected to Begin Trading on a Split-Adjusted Basis on August 31, 2026SOLANA BEACH, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today announced a 1-for-9 reverse stock split (“Reverse Split”) of the Company’s common stock (“Common Stock

SOLANA BEACH, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that the Japanese Patent Office has issued a notification of allowance with a Decision to Grant for the Company’s patent application covering the intended commercial form

The Patent Claims are for the Intended Commercial Formulation of ART27.13 Expected to Extend Patent Protection for ART27.13 through 2041 SOLANA BEACH, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that the United States Patent and Trademark Office has issued

Clinical and Scientific Progress Across the Pipeline Supports Multiple Upcoming MilestonesSOLANA BEACH, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological, or neurological conditions, today provided a business update and announced its financial and operational results for the se

Review Article Now Published in the British Journal of Clinical Pharmacology Finds Widely Sold Non-Prescription CBD Products at Doses Administered Failed to Provide Adequate Exposure for Positive Biological Effect Underscores the Need for Optimized CBD Formulations and Rigorous, Evidence-Based Drug Development SOLANA BEACH, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating l

Osteoarthritic Pain Model Results Further Validate FABP5 as a Novel Therapeutic Target in Pain ManagementSOLANA BEACH, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced new data supporting the therapeutic potential of ART26.12, its pr

Every proxy submitted helps establish the quorum needed to conduct the Company's Annual Meeting, regardless of how shareholders choose to voteSOLANA BEACH, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today reminds shareholders to vote their shares in advance of the Compan

Expands potential benefit for treating neuropathic pain in cancer patients, particularly those experiencing weight loss due to cancer Findings suggest broader utility in cancer supportive care, building on interim findings from CAReS Phase 2 clinical study which demonstrated improvements in body weight, lean body mass and activity levels SOLANA BEACH, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company), a clinical-stage pharmaceutical comp